Literature DB >> 3240721

Contribution of serotonergic systems to maintenance of blood pressure in anaesthetised normotensive Wistar Kyoto and conscious spontaneously hypertensive rats.

B G Schulz1, G Schröder, G Stock.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3240721     DOI: 10.2165/00003495-198800361-00018

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  7 in total

1.  Pharmacological profile of a new potent 5-hydroxytryptamine (5-HT2) alpha 1-receptor antagonist.

Authors:  G Schröder; R Beckmann; K P Gerbling; O Loge; B Maass; B Müller; D Seidelmann; H H Schneider; B G Schulz; C S Stürzebecher
Journal:  Arzneimittelforschung       Date:  1988-06

2.  Cardiovascular effects in the rat of ketanserin, a novel 5-hydroxytryptamine receptor blocking agent.

Authors:  B Persson; T Hedner; M Henning
Journal:  J Pharm Pharmacol       Date:  1982-07       Impact factor: 3.765

3.  Hypertension mediated by the activation of the rat brain 5-hydroxytryptamine receptor sites.

Authors:  M K Krstić; D Djurković
Journal:  Experientia       Date:  1976-09-15

4.  Involvement of serotonin in the central regulation of blood pressure: evidence for a facilitating effect on sympathetic nerve activity.

Authors:  R B McCall; S J Humphrey
Journal:  J Pharmacol Exp Ther       Date:  1982-07       Impact factor: 4.030

Review 5.  Review of the role of the central serotonergic neuronal system in blood pressure regulation.

Authors:  D M Kuhn; W A Wolf; W Lovenberg
Journal:  Hypertension       Date:  1980 May-Jun       Impact factor: 10.190

6.  Sympathetic alterations after midline medullary raphe lesions.

Authors:  R B McCall; L T Harris
Journal:  Am J Physiol       Date:  1987-07

7.  Association between increased serotonin metabolism in rat brainstem nuclei and development of spontaneous hypertension.

Authors:  M Koulu; J M Saavedra; M Niwa; M Scheinin; M Linnoila
Journal:  Brain Res       Date:  1986-04-16       Impact factor: 3.252

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.